PJSC Magnitogorsk Iron and Steel Works: MMKnotifies on second extention of consent solicitation process
PJSC Magnitogorsk Iron & Steel Works (MOEX: MAGN; LSE: MMK) notifies on the second extension of the Consent Solicitation for its outstanding U.S.$500,000,000 4.375 per cent. Guaranteed Notes due 2024.
On 9 June 2022, PJSC Magnitogorsk Iron & Steel Works (the “Guarantor”) announced extension of consent solicitation in relation to the outstanding U.S.$500,000,000 4.375% Notes due 2024 issued by MMK International Capital DAC (the “Issuer”) (ISIN: XS1843434959 (Regulation S) / US553142AA88 (Rule 144A); Common Code: 111730628 (Regulation S) / 111730628 (Rule 144A Common code)) (the “Notes”) on the terms and subject to the conditions set forth in the Consent Solicitation Memorandum dated 6 June 2022 (the “Consent Solicitation Memorandum”). Capitalized terms used, but not defined herein, shall have the meanings given to them in the Consent Solicitation Memorandum.
The Guarantor is pleased to announce that significant progress has been made in obtaining support from investors and thanks those Noteholders, who have already submitted their Consent instructions. In response to requests from a number of accounts requiring additional time in order to pass internal approvals and submit their signatures, the Guarantor announces further extension. The Guarantor thanks all investors who have provided their feedback on the terms of Consent and amendments sought. The Guarantor hereby notifies the Noteholders that it has decided to further extend the Consent Deadline period from 16 June 2022 (4 p.m. (London time)) to 30 June 2022 (4 p.m. (London time)) (the “Updated Consent Deadline”).
Amendments to the Consent Solicitation are limited to the Updated Consent Deadline, as outlined above. All other terms of the Consent Solicitation will remain the same.
The Guarantor strongly encourages those Noteholders that have not yet participated in the Consent Solicitation to liaise at their earliest convenience with its Investor Relations department and/or Rybalkin, Gortsunyan, Dyakin and Partners Advocates Bureau (“RGD”) directly to obtain a copy of the Consent Solicitation Memorandum and to discuss other related matters. Noteholders who have already delivered Consent Instructions in the Consent Solicitation will be deemed to have consented to the Amendments unless they validly revoke their Consents prior to the earlier of the Effective time and the Updated Consent Deadline.
All documentation relating to the Consent Solicitation, together with any updates, will be available upon request to RGD at MMKconsentsolicitation2022@rgd.legal. In your communique, please also confirm the aggregate notional amount of the Notes that you hold and the location of the depository.
Noteholders may contact RGD via email at MMKconsentsolicitation2022@rgd.legal if they require assistance.
Should the Noteholders have any additional questions, please contact with the Guarantor’s Investor Relations department via email at: ir@mmk.ru.
| ISIN: | US5591892048 |
| Category Code: | MSCM |
| TIDM: | MMK |
| LEI Code: | 253400XSJ4C01YMCXG44 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005233/en/
Contact information
INVESTOR RELATIONS DEPARTMENT
Veronika Kryachko
+7 (3519) 25-75-01
kryachko.vs@mmk.ru
COMMUNICATIONS DEPARTMENT
Dmitriy Kuchumov
+7 (499) 238-26-13
kuchumov.do@mmk.ru
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SciencePower Collaborates to Advance Research on Postbiotics in Breast Cancer Biology9.12.2025 14:00:00 EET | Press release
SciencePower, a next-generation postbiotic platform company, today announced that it has entered into a license agreement with Mayo Clinic. The agreement enables collaborative research led by Mayo Clinic investigators to explore the potential of SciencePower’s proprietary postbiotic compositions in breast cancer biology. The collaboration will focus on understanding how specific microbiome-derived compositions influence immune and cellular pathways relevant to breast cancer. Early preclinical findings are currently planned to be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2025. “This milestone marks an important step in validating our technology through rigorous scientific collaboration,” said Robin Albin, SciencePower Co-Founder, Marketing & Communications. “We are honored to work with Mayo Clinic researchers to deepen the understanding of postbiotics and their potential role in advancing human health.” Mayo Clinic has a financial interest in SciencePower
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET9.12.2025 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company’s commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders’ perspectives on the current treatment landscape and the significant unmet need in treating both TRD and PTSD. The company’s collaboration partners will discuss patient care pathways, provider economics for multi-hour treatments, and the development of treatment models in TRD. Compass Pathways’ management team will review commercial readiness activities and the emerging profile of COMP360 in TRD, as well as highlight the unmet need in post-traumatic stress disorder (PTSD) and provide details of the planned late-stage program for COMP360 in
Brands Poised for Growth: NIQ Identifies the Strategies Behind 2025’s Top Performing Innovations9.12.2025 13:00:00 EET | Press release
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its 4th Annual Innovation Vitality Report, revealing the strategies that are helping brands achieve multi-year growth from their innovation pipelines. Drawing on data from over 70,000 manufacturers across 130 categories, the report highlights the practices that double a company’s likelihood of expanding overall sales through top performing innovation. As retailers accelerate shelf refresh cycles and private label competition intensifies, brands are under increasing pressure to design innovations with staying power. NIQ’s findings show that top performing innovators consistently follow a repeatable formula, rooted in strong consumer-led ideas, early performance signals, and cross functional alignment, to build products that deliver long-term, incremental growth across global markets. Key Findings from the 2025 Innovation Vitality Report Winning Innovation Starts Before Launch Brands that invest in true innov
Klarna Now Available on Apple Pay to Customers in France and Italy9.12.2025 12:49:00 EET | Press release
Klarna, the global digital bank and flexible payments provider, has made its flexible payment products available when checking out on Apple Pay in France and Italy. Millions of eligible shoppers can now choose Klarna at checkout online and in-app using their iPhone and iPad, or in-store using their iPhone, and this innovative capability delivers even more convenience, control, and transparency to even more customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209410835/en/ The continued expansion follows strong consumer adoption and momentum in Denmark, Spain, Sweden, the U.S., UK and Canada, where Klarna’s flexible payment options have become a popular way to pay with Apple Pay. With today’s launch, consumers across eight major markets can now choose to shop with Klarna through Apple Pay’s simple and secure experience, and consumers have more choice and flexibility in how they can pay. “We’ve seen incredible exciteme
DNP Achieves 10nm Line Pattern Resolution on Nanoimprint Template for Cutting-Edge Semiconductors9.12.2025 12:12:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced the development of a nanoimprint lithography (NIL) template featuring a circuit line width of 10 nanometers (nm: 10-9 meter). The new template enables patterning for logic semiconductors equivalent to the 1.4nm generation and meets the miniaturization needs of cutting-edge logic semiconductors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208175160/en/ Template for nanoimprint Background and Aims In line with the shift to more sophisticated devices seen in recent years, demands have emerged for even greater miniaturization in cutting-edge semiconductors, leading to advances in Extreme Ultra-Violet (EUV) lithography-based production. EUV lithography, however, requires substantial capital investment, energy consumption, and operating costs in building production lines and the exposure process. Since 2003, DNP has been developing NIL templates and has successf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom